Evidence That Health Care Costs Will Not Be Controlled

Writing in the New Republic, Jonathan Cohn thinks he has found the reason forPhRMA’s support of the current legislation. Apparently back in March the  “global research and consulting firm” IMS Health projected negative growth for the drug industry from 2008 to 2013. But now, with the prospects of health legislation growing, it is projecting annual growth of 3.5% for the same period. That level of growth makes the $80 billion in concessions by the industry seem like a good investment.

SOURCE:

New Republic